AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00156117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01474915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
Study NCT01474915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: Subject will receive 25 mg of Promethazine IV around anesthesia induction
Study NCT01474915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
Study NCT01636934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
Study NCT03916978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP intra ovarian infusion
Description: Autologous PRP intra ovarian infusion
Study NCT03916978 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous PFP intra ovarian infusion
Description: Autologous PFP intra ovarian infusion
Study NCT02431845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
Study NCT04084288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
Study NCT04084288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulator
Description: Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
Study NCT04421768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cervical exam training
Description: Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
Study NCT02587403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fortiva™ Porcine Dermis
Description: Fortiva Porcine Dermis implantation during repair of complex ventral hernia
Study NCT00156117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 15 mg QD
Study NCT02168361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2b
Description: 1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
Study NCT02587403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Strattice tissue matrix implanted during repair of complex ventral hernia
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: Given orally
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: Given orally
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: goserelin acetate
Description: Given subcutaneously or intramuscularly
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously or intramuscularly
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: letrozole
Description: Given orally
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT02168361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
Study NCT02168361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
Study NCT02168361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 12 weeks of combination sofosbuvir and simeprevir
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leuprolide acetate
Description: Given subcutaneously or intramuscularly
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given subcutaneously or intramuscularly
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen citrate
Description: Given PO
Study NCT01674140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO
Study NCT01674140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00098475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Given PO
Study NCT00098475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study NCT01661543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beans
Description: 120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
Study NCT01661543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (rice)
Description: 110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
Study NCT01636934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
Study NCT01636934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
Study NCT01636934 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
Study NCT04231409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Spectra WaveWriter SCS System
Description: The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
Study NCT02168361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: 12 weeks of combination sofosbuvir and simeprevir
Study NCT03800667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 1000 MG
Description: 1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
Study NCT00111020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
Study NCT03037502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)
Description: Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
Study NCT03693742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT scan
Description: Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes.
Study NCT03693742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 18F-DCFPyL PET/CT scan
Description: Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes.
Study NCT03693742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
Study NCT03693742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSG drink
Description: Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
Study NCT00329732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivicaine and 2% lidocaine
Description: The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
Study NCT00329732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: matching volume of saline (placebo)
Study NCT04111887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based therapy
Description: College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
Study NCT01214343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib with Low-dose FP
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
Study NCT01214343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
Study NCT02543580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric acupoint stimulation
Description: electrodes are attached o the skin and electric stimulation is given
Study NCT02543580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrode attached but no stimulation
Description: electrodes are attached o the skin but no stimulation is given
Study NCT02834039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume 6 ml/kgBW
Description: Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
Study NCT02834039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume 10 ml/kgBW
Description: Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
Study NCT02051686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
Study NCT02051686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive a similar volume load of normal saline and maintenance doses.
Study NCT02304718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stationary bike
Study NCT03159221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BFST for Teens with Type 2 Diabetes
Description: BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
Study NCT01601730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil and Escitalopram
Description: Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
Study NCT01601730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
Study NCT01601730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Treatment 2: Modafinil 200 mg + Escitalopram 0.
Study NCT01601730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Treatment 3: Modafinil 0 + Escitalopram 20 mg.
Study NCT04449601 — intervention group
Intervention type: OTHER
Intervention: clinical assesment
Description: Comparison of Hypertensive group and normotensive group
Study NCT01661543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peas
Description: 120 grams of peas will be consumed 5 out of 7 days per week
Study NCT01445275 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of Cancer Risk Factors
Description: Ancillary studies
Study NCT01445275 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Ancillary study
Study NCT01445275 — intervention group
Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Ancillary studies
Study NCT04470011 — intervention group
Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study NCT04470011 — intervention group
Intervention type: OTHER
Intervention: Interviews with service providers
Description: Clinicians and lay staff will be interviewed regarding the ART initiation process.
Study NCT01292031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
Study NCT01292031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2 g/iv/ 8 h. 30 minutes infusion
Study NCT03478956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
Study NCT02610426 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01722669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoquercetin or quercetin
Description: Single dose PK/PD study
Study NCT01722669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoquercetin or quercetin
Description: Single dose PK/PD study
Study NCT02128022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (7-36) amide
Description: Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
Study NCT02128022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) amide
Description: Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
Study NCT02128022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Oral Glibenclamide 5mg
Study NCT04581811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged Proned Positioning
Description: Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
Study NCT04581811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Proning Arm
Description: Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
Study NCT03762590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doxy.me genetic education +/- Color Genomics genetic education
Description: Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
Study NCT03762590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Color Genomics genetic education
Description: Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
Study NCT02927964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02927964 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02927964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given IT
Study NCT01336699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
Study NCT01336699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSs2
Description: WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
Study NCT01336699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSs3
Description: WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
Study NCT04411992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Device
Description: The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT02828358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02828358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02828358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV